Kazia Therapeutics Hosts Virtual Event on NDL2 Cancer Therapy

PUBT · 2d ago
Kazia Therapeutics Hosts Virtual Event on NDL2 Cancer Therapy
  • Kazia Therapeutics will host a virtual event on Dec. 2, 2026, at 4 p.m. ET to discuss NDL2.
  • Management will review the nuclear PD-L1 protein degrader’s development, initially targeting metastatic breast cancer and colorectal cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via CNW (Ref. ID: 202611120700CANADANWCANADAPR_C3174) on November 12, 2026, and is solely responsible for the information contained therein.